The FDA's Center for Drug Evaluation and Research sent an untitled letter to online retailer Amazon for misbranding drugs and marketing unapproved drugs in violation of certain sections of the Federal Food, Drug and Cosmetic Act. In a letter sent to Amazon CEO Andy Jassy, the FDA said it identified 26 weight loss and sexual enhancement products being sold on Amazon that contained one or more of the active pharmaceutical drug ingredients tadalafil, sildenafil or vardenafil, that were not declared on the labeling of the products.
Kaiser Foundation Health Plan has filed a lawsuit accusing Merck and the firm manufacturing generics of its popular cholesterol drugs Vytorin and Zetia of delaying generic competition for the two drugs and violating antitrust laws. Kaiser Permanente's health plan claims it paid hundreds of millions more for the two cholesterol drugs as a result of a pay-for-delay scheme.
The FDA has allowed Emergent BioSolutions to resume production of the drug substance used in Johnson & Johnson's COVID-19 vaccine at its previously troubled plant, although the facility has yet to be fully authorized by the FDA and individual lots of vaccines still need to be inspected by the agency prior to shipment and administration, according to an unnamed administration official.
Eli Lilly's baricitinib was granted expanded emergency use authorization by the FDA as a COVID-19 drug that can be administered separately from Gilead's remdesivir. The expanded authorization was based on results from a trial involving 1,525 hospitalized COVID-19 patients that showed those treated with baricitinib had a lower risk of progressing to ventilator use or death compared with patients given standard of care.
McCormick & Co. is recalling several seasonings due to potential salmonella contamination discovered during routine FDA testing. The affected products were shipped to over 30 US states, Canada and Bermuda from June 20 to July 21.
With the country opening up, FDLI remains committed to providing high-quality educational programs in a way that keeps our members and event attendees safe. After discussions with our conference committees, and taking into account the unique aspects of each program and the need to remain flexible, we have revised the fall program to include two hybrid programs (both in-person and virtual) and one in-person program. All in-person plans are subject to change as needed to protect the health and safety of the FDLI community. View Programs
This webinar will delve into the chemistry of delta-8 THC and other psychoactive cannabinoids, how they are derived, possible safety concerns, and their similarities and differences from delta-9 THC. Speakers will discuss the legal status of these relatively new cannabinoids under FDA and DEA rules, the evolving nature of state bans, and the potential influence on policy discussions about other cannabis products. Register Now